Loading

Cecilia Brown

Cecilia Brown is an assistant editor for Mashup Media, the parent company of GU Oncology Now. Cecilia is a medical writer and editor with over four years of experience in publishing and journalism, as well as several years of research experience. She can be reached at CBrown@mashupmd.com.

Articles by Cecilia Brown

Cecilia Brown

Advanced Urothelial Carcinoma | September 22, 2022

The pretreatment albumin-globulin ratio can independently predict survival outcomes in patients with urothelial carcinoma.

Cecilia Brown

Advanced Urothelial Carcinoma | September 22, 2022

Researchers identified the top reason why some patients with urothelial carcinoma don't pursue treatment.

Cecilia Brown

Advanced Urothelial Carcinoma | September 22, 2022

Shilpa Gupta, MD, discusses recent developments in targeted molecular therapeutics for advanced bladder cancer.

Cecilia Brown

Advanced Urothelial Carcinoma | September 22, 2022

Enfortumab vedotin plus pembrolizumab led to an ORR of 73.3% in cisplatin-ineligible patients with urothelial cancer.

Cecilia Brown

Urothelial Carcinoma | September 1, 2022

Dr. Mary Beth Westerman, speaks on notable advances that she has see in bladder cancer throughout her career.

Cecilia Brown

Urothelial Carcinoma | September 1, 2022

Dr. Westerman speaks on what clinicians can do to improve pre-operative counseling for female patients with bladder cancer.

Cecilia Brown

Urothelial Carcinoma | September 1, 2022

Dr. Mary Beth Westerman provides insight on some of the main challenges in treating women with bladder cancer.

Cecilia Brown

Renal Cell Carcinoma | August 26, 2022

Treatment with an ICI plus a VEGF receptor inhibitor showed increased likelihood of obtaining an objective imaging response.

Cecilia Brown

Prostate Cancer | August 16, 2022

Failure-free survival rates between focal cryoablation and stereotactic body radiotherapy for prostate cancer no different.

Cecilia Brown

Muscle Invasive Urothelial Carcinoma | August 15, 2022

A trial utilized atezolizumab, a monoclonal antibody directed at the PD-L1 protein, in patients with MIBC.